American Thoracic Society - Sanofi Investor Call

LS mean change from baseline (L) ± 95% CI 0.32- 0.28- 0.24- 0.20- 0.16- 0.12- Change in Lung Function Over Time Pre-BD FEV1 LS mean difference (95% CI) Week 12: 83ml (42-125ml); p<0.001 Week 52: 83ml (38-128ml); p<0.001 0.08- 0.04- 0.00 -0.04- -0.08 I I II 024 Placebo Dupilumab 52 42 T T 8 12 24 36 44 Week LS mean change from baseline (L) ± 95% CI Post-BD FEV₁ 0.32- 0.28- Placebo Dupilumab 0.24- 0.20- 0.16- 0.12- 0.08- 0.04- 0.00- -0.04- -0.08- 024 8 12 24 Week 36 9. No. of participants with observed change from baseline Placebo 471 455 459 Dupilumab 467 457 454 439 446 439 435 449 443 ATS 2023 415 404 420 471456458 439 431 410 417 415 410 426 468457 454 448 436 434 417 417 423 26 52 52

View entire presentation